FDA Prodded to Push Bio-Innovation; Agency Eyes ‘Science Enclaves’

To boost biopharma innovation and U.S. competition in the sector, the FDA should incentivize precompetitive industry collaborations, promote public-private partnerships and wrap up integration of its information technology (IT) systems, a new Obama administration paper states. “Integrating and analyzing [FDA clinical] data could revolutionize the development of new patient treatments and allow researchers to address fundamental scientific questions about how different patients respond to a therapy,” the White House Office of Science and Technology Policy (OSTP) said in its National Bioeconomy Blueprint.
Washington Drug Letter